Arbutus Biopharma
ABUS
4.13
-0.16
-3.76%
Arbutus Biopharma
US · ABUS
#3365 by market cap
Listed 2015
4.13
-0.16
-3.76%
Live - 5344 symbols - heartbeat 33s ago
· 2026-10-08 10:00
Pre-market
4.23
-1.40%
After-hours
4.30
+0.23%
- Market cap
- 817.94M
- P/E (TTM)i
- 5.23
- P/Bi
- 3.16
- EPSi
- -0.17
- Div yieldi
- 0.00%
- 52W posi
- 32%
Reader sentiment
Are you bullish or bearish on ABUS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.11, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +128.21% YoY
Margins
- Operating margin
- -192.08%
- Net margin
- -237.88%
Key ratios & quality
- Altman Z-Scorei
- 7.11
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.95M | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 16.00M | 17.73M | 14.85M | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Research & development | 57.93M | 57.60M | 49.34M | 65.50M | 84.41M | 73.70M | 54.04M | 25.24M |
| Operating profit | -70.17M | -71.35M | -57.27M | -71.65M | -63.22M | -78.03M | -69.97M | -27.05M |
| Pretax profit | -61.34M | -166.38M | -63.75M | -76.25M | -65.01M | -72.85M | -69.92M | -33.50M |
| Tax | -4.28M | -12.66M | -- | 0 | 4.44M | 0 | -- | -- |
| Net profit | -57.06M | -153.72M | -63.75M | -76.25M | -69.46M | -72.85M | -69.92M | -33.50M |
| Basic EPS | -1 | -3 | -1 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -1.21 | -2.89 | -1.00 | -0.83 | -0.46 | -0.44 | -0.38 | -0.17 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.76M | 10.74M | 529.00K | 1.05M | 179.13M | 1.01M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.83M | 3.33M | 3.04M | 3.69M | 5.89M | 3.87M |
| Research & development | 8.96M | 5.50M | 5.78M | 5.01M | 4.12M | 2.90M |
| Operating profit | -13.03M | 1.91M | -8.29M | -7.64M | 169.12M | -5.75M |
| Pretax profit | -24.53M | 2.52M | -7.74M | -3.76M | 169.70M | -5.14M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -24.53M | 2.52M | -7.74M | -3.76M | 169.70M | -5.14M |
| Basic EPS | 0 | 0 | 0 | 0 | 1 | 0 |
| Diluted EPS | -0.13 | 0.01 | -0.04 | -0.01 | 0.87 | -0.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 129.23M | 93.83M | 127.70M | 160.66M | 151.14M | 132.03M | 127.32M | 94.46M |
| Cash & ST investments | 124.62M | 90.83M | 123.27M | 155.32M | 146.91M | 126.00M | 122.62M | 91.47M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 227.91M | 105.54M | 137.08M | 204.49M | 195.42M | 144.40M | 131.71M | 94.62M |
| Total current liabilities | 11.24M | 7.83M | 9.54M | 11.22M | 32.86M | 22.49M | 15.62M | 6.01M |
| Short-term debt | -- | 340.00K | 390.00K | 383.00K | 372.00K | 425.00K | 483.00K | 547.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 27,671,000.00 | 32,791,000.00 | 35,114,000.00 | 35,046,000.00 | 58,567,000.00 | 38,383,000.00 | 34,341,000.00 | 18,042,000.00 |
| Total equity | 200.23M | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M | 97.37M | 76.58M |
| Retained earnings | -805.22M | -970.09M | -1.05B | -1.13B | -1.20B | -1.28B | -1.35B | -1.38B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 116.81M | 103.12M | 97.44M | 94.46M | 277.01M | 273.88M |
| Cash & ST investments | 112.71M | 98.09M | 93.70M | 91.47M | 95.23M | 92.63M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 117.01M | 103.27M | 97.71M | 94.62M | 277.16M | 274.03M |
| Total current liabilities | 19.43M | 5.02M | 5.18M | 6.01M | 5.11M | 3.36M |
| Short-term debt | 563.00K | 514.00K | 531.00K | 547.00K | 631.00K | 514.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 37,853,000.00 | 20,291,000.00 | 20,311,000.00 | 18,042,000.00 | 16,987,000.00 | 15,292,000.00 |
| Total equity | 79.16M | 82.98M | 77.40M | 76.58M | 260.18M | 258.73M |
| Retained earnings | -1.37B | -1.37B | -1.38B | -1.38B | -1.21B | -1.22B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -67.87M | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M | -64.85M | -39.64M |
| Depreciation & amortization | 2.18M | 2.03M | 1.98M | 1.75M | 1.43M | 1.40M | 1.38M | 363.00K |
| Free cash flow | -69.00M | -71.60M | -51.67M | -68.34M | -35.87M | -86.94M | -65.03M | -39.64M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 18.60M | 86.30M | 134.67M | 20.32M | 29.85M | 44.12M | 0 |
| Ending cash balance | 36.94M | 31.80M | 52.25M | 109.28M | 30.78M | 26.29M | 36.33M | 18.01M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.39M | -15.75M | -5.82M | -4.68M | -8.11M | -6.02M |
| Depreciation & amortization | 330.00K | 11.00K | 11.00K | 11.00K | 11.00K | 11.00K |
| Free cash flow | -13.39M | -15.75M | -5.82M | -4.68M | -8.11M | -6.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 37.08M | 37.41M | 22.41M | 18.01M | 23.71M | 19.17M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -64.95 | -3,450.29 | -- | -144.90 | -45.35 | -59.99 | -68.76 | -38.52 |
| ROA %i | -28.88 | -98.89 | -62.54 | -51.75 | -34.74 | -42.88 | -50.65 | -29.60 |
| ROIC %i | -67.48 | -2,026.36 | -- | -134.26 | -44.89 | -63.27 | -73.99 | -42.59 |
| 5-year avg ROE %i | -58.12 | -737.63 | -- | -- | -- | -- | -- | -71.50 |
| EBIT margin %i | -1,028.02 | -2,732.84 | -863.96 | -667.91 | -162.19 | -399.04 | -1,130.82 | -237.19 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.50 | 11.99 | 13.38 | 14.32 | 4.60 | 5.87 | 8.15 | 15.73 |
| Quick ratioi | 11.22 | 11.76 | 13.06 | 13.92 | 4.51 | 5.68 | 8.01 | 15.47 |
| Debt / assetsi | 0.00 | 3.18 | 2.18 | 1.28 | 1.12 | 1.22 | 0.98 | 0.79 |
| LT debt / equityi | -- | -- | -- | 1.32 | 1.33 | 1.27 | 0.83 | 0.26 |
| Interest coveragei | -270.42 | -77.93 | -14.89 | -25.69 | -36.67 | -157.71 | -509.36 | -344.37 |
| Revenue CAGR (3Y) %i | -36.55 | 59.16 | -13.55 | 22.72 | 86.54 | 37.93 | -17.50 | -28.80 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -79.02 | -52.82 | -45.88 | -38.52 | 94.73 | 89.58 |
| ROA %i | -57.29 | -41.21 | -35.50 | -29.60 | 81.55 | 81.13 |
| ROIC %i | -84.09 | -57.26 | -50.17 | -42.59 | 92.96 | 87.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,193.97 | -351.17 | -288.70 | -237.19 | 84.00 | 84.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.01 | 20.53 | 18.80 | 15.73 | 54.26 | 81.42 |
| Quick ratioi | 5.86 | 19.74 | 18.25 | 15.47 | 53.92 | 80.97 |
| Debt / assetsi | 1.02 | 1.05 | 0.94 | 0.79 | 0.23 | 0.19 |
| LT debt / equityi | 0.79 | 0.69 | 0.51 | 0.26 | -- | -- |
| Interest coveragei | -631.82 | -470.76 | -386.86 | -344.37 | 1,869.84 | 2,014.87 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 10:00:20 · For reference only, not investment advice and not tailored to your situation.